ARCHIVES

In Brief: FDA Oncology Div. Director Burke To Leave; Reed Is Branch Chief; NCAB Blasts Tobacco

This article is from The Cancer Letter archive.

Vol. 20 No. 42 | November 4, 1994

Download PDF Visit The Full Archive

Related Articles

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

October 15, 2004

ACS Prostate Cancer Recommendations Move Forward

August 7, 1992

Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable

April 26, 2013

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

NCI-Approved CTEP Trials For The Month of July

July 27, 2012

Evaluation Finds OIG Provides PIs With Flexibility

June 14, 1991